No Detail Found!

Immunological and Molecular Investigation of BCR-ABL1 in Samples of Iraqi Chronic Myeloid Leukemia Patients

Author(s)
Farooq I. Mohammad College of Science, Kirkuk University,,Iraq
Alaa R. Nadim Department of Biology, Kirkuk University,,Iraq
Abstract
Background: Chronic myelogenous leukemia (CML) is a blood malignancy that affects hematopoietic stem cells. Also, it is commonly identified by the Philadelphia chromosome. This chromosome produces a protein with strong tyrosine kinase activity and functions as a tumorigenic factor. Objective: This study aimed to investigate the Immunological and Molecular of BCR-ABL1 gene expression and ABL1 protein in patients admitted to the Oncology and Hematology Center of the Kirkuk Governorate, Iraq. Materials and Methods: A study was conducted in Kirkuk Governorate, Iraq, from the beginning of November 2022 to May 2023 on Chronic Myeloid Leukemia patients in the Oncology and Hematology Center, which was hospital-based and cross-sectional. The study comprised fifty-three patients with Chronic Myeloid Leukemia. They were diagnosed using a complete blood count (CBC), a molecular test BCR-ABL1, and an immunological test ABL1 protein. The research did not include patients with missing data and those without consent. Fifty-three peripheral blood samples from 53 CML patients at chronic stages of CML were taken, and using automated Gene Xpert BCR-ABL1 Ultra assay, BCRABL1 transcript quantification was conducted on them. Results: The research included fifty-three patients in total (27 males, 28 females), with a mean age of 47.3± 12.8 years. The average of BCR_ABL1 by RT_ qPCR 3.22± 0.09 and the mean of ABL1 by Enzyme-linked Immune sorbent assay (ELISA) reigned is 981± 891. Conclusion: Values of the quantitative realtime reverse transcription polymerase chain reaction (RT_ qPCR) by Gene Xpert Ultra level range between 38.62 and 0.00 with a mean of 3.22± 0.09. The RT_ qPCR level showed that 22% of the patients were in good condition, 11% of them had a strong response to treatment, and other 11% showed a complete cytogenetic response (CCyR), which is also a good outcome; however, 78% of the patients either not taking their medication, or there is true resistance. These two methods used different techniques; the former is a nuclear-derived method that detects the presence of specific genetic materials of any pathogen; in the current research, BCR-ABL1 is the target. The latter is a test that detects and measures antibodies, antigens, proteins, and glycoproteins in biological samples, so ABL1 is the target.
Publication Details
Page(s) 94-98
Published Journal: Journal of Pioneering Medical Sciences, Volume: 13, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
treatment, Leukemia, BCR-ABL1, CML, p190, p210, B cell
References
Soverini S.,Mancini M.,Bavaro L.,Cavo M.,Martinelli G. .2018 .Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Molecular Cancer, 17(1) : 1-15.
Foulon S.,Cony-Makhoul P.,Guerci-Bresler A.,Delord M.,Solary E.,Monnereau A.,Tubert-Bitter P. .2019 .Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study. Cancer Medicine, 8(6) : 3296-3304.
Chereda B.,Melo J. V. .2016 .The biology and pathogenesis of chronic myeloid leukemia. Chronic Myeloid Leukemia, : 17-39.
Score J.,Calasanz M. J.,Ottman O.,Pane F.,Yeh R. F.,SobrinhoSimões M. A.,Grand F. H. .2010 .Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia, 24(10) : 1742-1750.
Reckel S.,Gehin C.,Tardivon D.,Georgeon S.,Kükenshöner T.,Löhr F.,Hantschel O. .2017 .Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase. Nature Communications, 8(1) : 2101.
Bernt K. M.,Hunger S. P. .2014 .Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Frontiers in Oncology, 4 : 54.
Soverini S.,Bassan R.,Lion T. .2019 .Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. Journal of Hematology & Oncology, 12(1) : 1-14.
Hochhaus A.,Baccarani M.,Silver M.,Schiffer C.,Apperley J. F.,Cervantes F.,Hehlmann R. .2020 .European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 34(4) : 966-984.
Dalle Abou,Kantarjian I.,Short H. M.,Konopleva N. J.,Jain M.,Garcia-Manero N.,Ravandi G.,F. G. .2019 .Philadelphia chromosomepositive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. American Journal of Hematology, 94(12) : 1388-1395.
Cutler J. A.,Tahir R.,Sreenivasamurthy C.,Renuse S.,Nirujogi R. S.,Pandey A. .2017 .Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis. Leukemia, 31(7) : 1513-1524.
Müschen M. .2019 .Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformation. Nature Reviews Immunology, 19(5) : 337-348.
Chan L. N.,Müschen M. .2017 .B-cell identity as a metabolic barrier against malignant transformation. Experimental Hematology, 53 : 1-6.
Hochhaus A.,Baccarani M.,Silver M.,Schiffer C.,Apperley J. F.,Cervantes F.,Hehlmann R. .2020 .European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 34(4) : 966-984.
Hochhaus A.,Saussele S.,Rosti G.,Mahon F. X.,Janssen J. J.,Hjorth-Hansen H.,Buske C. .2017 .Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Annals of Oncology, 28 : iv41-iv51.
Baccarani M.,Deininger M. W.,Rosti G.,Hochhaus A.,Soverini S.,Apperley J. F.,Hehlmann R. .2013 .European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. The Journal of the American Society of Hematology, 122(6) : 872-884.
Amna M. B.,Siddiqui A. A.,Wajid Z.,Moin A.,Khan A. .2018 .Presentations in patients of chronic myeloid leukemia; an observational study focusing on the association of haematological parameter on gender. Cancer Sci Res Open Access, 5(1) : 1-5.
Jbireal J. M.,Azab A. E.,Alzahani S.,Elshareef M. .2019 .Haematological and cytogenetic changes in CML patients treated with imatinib mesylate in Western Libya. Hematol Transfus Int J, 7(3) : 50-7.
Al-abady .2021 .Clinico-Hematological Profile in Patients with Chronic Myeloid Leukemia. Annals of the College of Medicine, Mosul, 43(1) : 1-9.
Jamal S. I.,Ranjan A.,Choudhary V. N.,Kumar K.,Agrawal R.,Kumar S. .2022 .Clinico-Hematological Profile and Bone Marrow Correlation of Chronic Myeloid Leukemia: A Multiparameter Study in a Tertiary Care Hospital. European Journal of Molecular & Clinical Medicine, 9(3) : 4687-4695.
Lee J. P.,Birnstein E.,Masiello D.,Yang D.,Yang A. S. .2009 .Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study. Journal of Hematology & Oncology, 2(1) : 1-8.
Ngono A. P. B.,Tipane P. A.,Njonnou S. R. S.,Timnou A. T.,Sango A. J. F.,Ndom P.,Mbanya D. .2020 .Hematobiological Profile of Patients with Chronic Myeloid Leukemia at the Diagnosis in Yaoundé: A Cross-Sectional Study. Open Journal of Blood Diseases, 10(04) : 110-123.
Ferrand C.,Deschamps M.,Levitas A.,Lockwood C.,Payton J. E.,Uy G. L.,Day G. J. .2017 .Xpert® BCR-ABL ultra, a high sensitivity assay, demonstrates a limit of detection Reaching MR4. 5 and below. Blood blood 130 (Suppl_1), : 1610.
Aitken M. J.,Benton C. B.,Issa G. C.,Sasaki K.,Yilmaz M.,Short N. J. .2021 .Two cases of possible familial chronic myeloid leukemia in a family with extensive history of cancer. Acta Haematologica, 144(5) : 585-590.
0

Citations

0

Downloads

33

Views